Rosiglitazone and heart failure: the controversy and clinical implications.
In this issue of Congestive Heart Failure, the editor of this department addresses a topic on which there is conflicting data. Dr Tepper selected 2 of the most relevant abstracts for review. His comments on the conflicting data-and the polarized viewpoints among physicians that often result-provide insights on the clinical implications of the controversy.
Virk
Imran S
IS
Wayne State University, Detroit, MI, USA.
Ruby
Rubinder S
RS
Tepper
David
D
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006333:Heart Failure / Q000503:physiopathology*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000139:chemically induced* / Q000453:epidemiology / Q000401:mortality; D018570:Risk Assessment; D012307:Risk Factors; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects*; D014481:United States / Q000453:epidemiology
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone